<DOC>
	<DOCNO>NCT00978172</DOCNO>
	<brief_summary>The present study aim investigate ass possible neurological neuropsychiatric event young child west Africa uncomplicated P. falciparum malaria 3-day treatment Artequin Paediatric `` real life condition . ''</brief_summary>
	<brief_title>Safety Efficacy Study Artesunate Mefloquin Children With Uncomplicated Malaria</brief_title>
	<detailed_description>The study aim investigate safety profile Artequin Paediatric 3-day treatment child uncomplicated P. falciparum malaria `` real life condition '' West Africa . Important parameter , concomitant medication , patient 's medical history disease , differential WBC count , presence parasitaemia well patient 's compliance evaluate . Detailed record possible AEs SAEs enable additionally assessment safety effectiveness Artequin Paediatric period 63 day follow treatment initiation . The present study primarily serve detect ass possible neuropsychiatric neurological event young child use standardized questionnaire axamination .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<criteria>Body weight ≥ 10 kg ≤ 20 kg . Presence acute uncomplicated P. falciparum malaria diagnosis confirm positive blood smear asexual form P. falciparum . Counts asexual form P. falciparum : 2'000 250'000 parasite per µL blood . Presence fever define axillary temperature ≥37.5 °C ( ≥ 38 °C oral , rectal tympanic temperature ) history fever within last 24 hour . Written inform consent provide patient parent guardian . If person unable write , thumb print witness consent permit . Willingness ability patient parent guardian comply study protocol duration study . Patients able take oral medication . Patients severe/complicated malaria define World Health Organization , 2000 , Severe falciparum malaria ( 18 ) . Known history evidence clinically significant disorder : neurological , psychiatric ( depression , psychosis schizophrenia ) , cardiovascular ( include arrhythmia ) , pulmonary , metabolic , gastrointestinal , endocrine disease malignancy . Patients history epilepsy convulsion . Patients receive antimalarial treatment within 7 day prior enrolment include substance antimalarial activity , e.g . antibiotic ) treatment mefloquine within 30 day prior enrolment . Patients hypersensitivity allergic reaction artemisinins mefloquine chemically relate entity ( e.g . quinine ) . Patients participate investigational drug trial within 30 day prior enrolment . Patients vomit 3 time within 24 hour enrolment 3 copious liquid stool within 24 hour . Patients know renal impairment . Patients require parenteral treatment . Patients splenectomy . Known immunocompromised patient receive immunosuppressive agent and/or patient know human immunodeficiency virus ( HIV ) infection .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>